Trust Co. of Toledo NA OH Purchases 136 Shares of Abbott Laboratories (NYSE:ABT)

Trust Co. of Toledo NA OH increased its position in Abbott Laboratories (NYSE:ABT) by 0.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 72,859 shares of the healthcare product maker’s stock after acquiring an additional 136 shares during the period. Abbott Laboratories comprises approximately 1.1% of Trust Co. of Toledo NA OH’s holdings, making the stock its 18th largest position. Trust Co. of Toledo NA OH’s holdings in Abbott Laboratories were worth $8,241,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Groupama Asset Managment grew its stake in shares of Abbott Laboratories by 22.2% in the third quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 41,557 shares during the period. Future Financial Wealth Managment LLC bought a new stake in Abbott Laboratories in the 3rd quarter worth approximately $31,000. Itau Unibanco Holding S.A. bought a new position in shares of Abbott Laboratories during the 2nd quarter valued at $32,000. Peterson Financial Group Inc. purchased a new position in shares of Abbott Laboratories in the 3rd quarter worth $32,000. Finally, Valued Wealth Advisors LLC increased its position in Abbott Laboratories by 78.4% during the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after acquiring an additional 127 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Oppenheimer started coverage on Abbott Laboratories in a research report on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 target price on the stock. Morgan Stanley boosted their target price on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 17th. Jefferies Financial Group lifted their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the company a “hold” rating in a research report on Thursday, October 17th. UBS Group lifted their price target on shares of Abbott Laboratories from $143.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Finally, Evercore ISI increased their target price on Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research report on Thursday, January 2nd. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $131.57.

Abbott Laboratories Stock Up 0.2 %

Shares of ABT stock traded up $0.24 on Monday, hitting $112.55. The stock had a trading volume of 841,658 shares, compared to its average volume of 4,229,947. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a one year low of $99.71 and a one year high of $121.64. The business has a 50 day moving average price of $115.33 and a 200 day moving average price of $112.54. The company has a market cap of $195.21 billion, a PE ratio of 34.21, a P/E/G ratio of 2.69 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The business had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $10.55 billion. During the same period last year, the business posted $1.14 EPS. The business’s revenue was up 4.9% compared to the same quarter last year. Research analysts anticipate that Abbott Laboratories will post 4.67 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 2.10%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s payout ratio is presently 71.73%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.